You have 9 free searches left this month | to do more

txa127

Txa127 is a drug used to treat COVID-19, Hematologic Malignancies, Anemia, and other conditions. Txa127 is being actively studied in 1 study and prior, has been studied in 3.

Top SponsorsTop SitesTop Investigators
Tarix PharmaceuticalsColumbia University Irving Medical CenterJeanine D'Armiento
Columbia UniversityRush University Medical CenterSean Collins
Vanderbilt University Medical CenterUniversity of Nebraska Medical Center
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
C
Completed
  • COVID-19
  • TXA127
  • Placebo
  • New York, New York
    Columbia University Irving Medical Center
2021-07-27
Jul 27, 2021
V
Recruiting
  • COVID-19
  • +2 more
  • TXA127
  • +3 more
  • Birmingham, Alabama
  • +64 more
2022-03-07
Mar 7, 2022
T
Completed
  • Thrombocytopenia
  • +3 more
  • TXA127
  • Placebo
  • Mobile, Alabama
  • +5 more
2017-10-10
Oct 10, 2017
T
Completed
  • Miscellaneous Peripheral Blood Cell Abnormalities
  • TXA127
  • Neupogen (filgrastim)
  • Tacoma, Washington
    Charles River Clinical Servies Norhtwest
2016-08-29
Aug 29, 2016
T
Withdrawn
  • Hematologic Malignancies
  • TXA127
  • Charlottesville, Virginia
    University of Virginia Cancer Center
2016-08-29
Aug 29, 2016
T
Terminated
  • Myelodysplastic Syndrome (MDS)
  • TXA127
  • Houston, Texas
    MD Anderson Leukemia Department
2016-08-29
Aug 29, 2016
T
Withdrawn
  • Cord Blood Transplant
  • +2 more
  • TXA127
  • Durham, North Carolina
    Pediatric Bone and Cord Blood, Duke Univ. Med. Center
2016-08-29
Aug 29, 2016